

Biological Biomarkers in Psoriatic Disease. A Review

KURT de VLAM, ALICE B. GOTTLIEB, and OLIVER FITZGERALD

ABSTRACT. Biomarkers are important in clinical practice because they allow quantitative assessment of diagnosis, disease processes, and treatment response. However, because development of biomarkers lags significantly behind that of drug development, absence of new and appropriate markers may slow the development of patient-tailored targeted therapies. At the 2007 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members of the biomarker committee discussed the possible use of biomarkers in psoriasis and psoriatic arthritis and reviewed the results of several studies of biomarkers in the pathogenesis, diagnosis, and treatment of both the inflammatory and dermatologic aspects of psoriatic disease. We review those discussions. (*J Rheumatol* 2008; 35:1443–8)

Key Indexing Terms:

PSORIATIC ARTHRITIS

PSORIASIS

BIOMARKERS

The US National Institutes of Health (NIH) Biomarkers and Surrogate Endpoint Working Group defines a biological biomarker as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to therapeutic intervention¹. Biological biomarkers include markers for drug effect or response, as well as for diagnosis, prognosis, or physiologic status information, such as disease activity or damage not related to drug effect. The US Food and Drug Administration (FDA) distinguishes 3 context-specific types of biomarkers: known valid biomarker, probable valid biomarker, and possible valid biomarker, based on the available scientific data for the biomarker (available from <http://www.fda.gov/cber/gdlns/pharmdntasub.htm>).

The NIH Working Group developed a 3-class system for biomarkers:

- Type 0: Markers of the natural history of a disease that correlate longitudinally with known clinical indices, such as symptoms over the full range of disease states.
- Type I: Markers that capture the effects of an intervention in accordance with the mechanism of action of the drug, even though the mechanism might not be known to be associated with clinical outcome.

- Type II: Markers that are considered surrogate endpoints because change in that marker predicts clinical benefit. These biomarkers must be relevant to the mode of actions of the drug and the pathophysiology of the disease and are thus more difficult to develop compared with Type 0 or Type I². Surrogate endpoints are intended to use clinical endpoints or hard outcome measures such as damage to predict clinical benefit based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence.

Biomarkers are important in clinical practice because they allow quantitative assessment of diagnosis, disease processes, and treatment response. They are used to select appropriate therapy and drug dosage to maximize effect, minimize toxicity, and monitor disease outcomes, and thus are the foundation of evidence-based medicine. However, because development of biomarkers lags significantly behind that of drug development, absence of new and appropriate markers may delay development of patient-tailored targeted therapies.

The development of new biomarkers is seriously hampered by conservative thinking, lack of quality control, and methodological issues such as inappropriate statistical analysis and validation. Within the rheumatology community under the umbrella of OMERACT (Outcome Measures in Rheumatology), a subcommittee is developing validation criteria for soluble biomarkers reflecting structural damage in rheumatoid arthritis (RA) and spondyloarthropathies (SpA)³. A special working group for the development of soluble biomarkers and synovial tissue biomarkers in psoriatic arthritis (PsA) is within the scope of the next OMERACT meeting 2008 (available from <http://www.omeract.org/>).

The techniques used to develop and measure biomarkers are diverse, e.g., *in vitro* analyses such as protein expression, gene patterns, or gene expression, and *in vivo* analyses such as those in functional imaging, which are still in early development in humans. Technologies available today may evaluate biochemical and chemical markers by proteomics and metabolomics; genetic markers using pharmacogenomics,

From the Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Department of Dermatology, Tufts–New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA; and Department of Rheumatology, St. Vincent’s University Hospital, Dublin, Ireland.

Supported by an unrestricted financial grant from Abbott, Centocor, Wyeth, Amgen, and UCB Pharma.

K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven; A.B. Gottlieb, MD, PhD, Department of Dermatology, Tufts–New England Medical Center and Tufts University School of Medicine; O. FitzGerald, MD, FRCP(FRCPI), Department of Rheumatology, St. Vincent’s University Hospital.

Address reprint requests to Dr. K. de Vlam, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium.

E-mail: Kurt.devlam@uz.kuleuven.ac.be

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2008. All rights reserved.

gene expression profiles, systems biology, and single-nucleotide polymorphisms (SNP); and structural markers using classical molecular imaging techniques.

Possible Use of Biomarkers in Psoriatic Disease

Outcome or clinical endpoints in PsA include diagnosis, inflammation, prognosis, disease activity, disease severity, damage, disability, and quality of life (QOL). Recent specific instruments have been attributed to disease activity or damage, but for other domains the instruments are still under development or not yet validated. Moreover, some instruments assess more than one domain, and others include composite scores (e.g., QOL).

Fulfilling the OMERACT standards for validity (truth, feasibility, and discrimination) is a major concern. For some domains, no gold-standard instrument has been identified. Additionally, different studies have used different instruments, making cross-comparisons difficult. A better approach might be to define domains based on the biology of the disease and then to look for the outcome of different biological processes such as the inflammatory process or the tissue response including damage.

Biomarkers in PsA can be determined in different compartments of the human body such as blood (serum/cellular compartment), synovial fluid (plasma/cellular compartment), urine, and synovial tissue. The technological possibilities are expanding and include flow cytometry, reverse transcription-polymerase chain reaction (RT-PCR), ELISA, immunohistochemistry, *in situ* hybridization, and DNA microarray. Other technologies, such as proteomics, metabolomics, and microarray may help to identify novel candidate biomarkers.

Biomarkers in Psoriatic Arthritis

Most candidate biomarkers in PsA have been borrowed from RA, which implies similarities in outcome or disease process between RA and PsA; however, recent clinical and translational research questions this premise. Increasingly, data demonstrate the different disease processes in RA and PsA, including genetics, the inflammatory process, and disease outcome. Thus, this “copy-paste” approach may lead to inappropriate choices of biomarkers and subsequently to incorrect conclusions. Compared with other forms of rheumatic disease, only limited data are available about biomarkers in PsA. Serum markers and biomarkers in synovial tissue as surrogates for disease activity or damage are most frequently studied, but these studies are hampered by the use of RA as a control group.

Diagnosis. A few biomarkers associated with diagnosis have been studied in patients in clinical trials. Gene expression in peripheral blood mononuclear cells (PBMC) for nucleoporin 63 kDa distinguished PsA patients from controls. Overexpression of MAP3K3 followed by CACNA1S can discriminate PsA from RA⁴. Immunohistology of synovial tissue in

PsA showed increased vascularity, CD3+ lymphocytes, and neutrophils compared with RA^{5,6}.

Disease activity. Biomarkers useful in monitoring disease activity must be increased in active disease, must correlate with disease activity, and must be sensitive to change. Most biomarkers of disease activity in PsA have not met these criteria.

Erythrocyte sedimentation rate (ESR), interleukin 6 (IL-6), IL-2R, IL-10, IL-1 receptor antagonist (IL-1RA), and hyaluronic acid have been studied in PsA, but only IL-1RA and ESR correlated with the number of swollen and tender joints, reflecting disease activity^{7,8}. Hyaluronic acid correlated with the degree of skin involvement but not with the joint disease⁹. The proinflammatory protein S100A12 was increased in PsA serum but not in synovial fluid and was sensitive to change under treatment with methotrexate¹⁰. ESR and C-reactive protein correlated well with response to tumor necrosis factor- α (TNF- α) blockade at the group levels in patients with PsA¹¹, but not with cytokine levels¹²; matrix metalloproteinase-3 (MMP-3) was increased in PsA patients with active disease and correlated with increased inflammatory parameters¹³. A decrease of MMP2 and MMP9 correlated well with clinical improvement in PsA (Table 1)¹⁴.

T lymphocyte subsets, which are increased in peripheral blood and synovial tissue in PsA, decreased with improvement in clinical signs following alefacept treatment¹⁵.

More than 300 genes showed an altered expression in PBMC obtained from patients with active PsA. Genes associated with the suppression of the innate and acquired immune response had a reduced expression, while others such as thioredoxin, S100A8, and S100A12 were increased. This latter finding corresponds with an increase in S100A12 previously demonstrated in the serum⁴.

Most work for biomarkers of disease activity in PsA has been undertaken in synovial tissue. Histological and immunohistochemical features studied both before and after treatment intervention have included analyses of cellular infiltration such as number of T cells, B cells, macrophages, vessels, and adhe-

Table 1. Serum biomarkers for disease activity in psoriatic arthritis.

Biomarker	Increased	Correlated to Disease Activity	Sensitivity to Change
Soluble interleukin 2 receptor	+	—	—
Interleukin 10	+	—	—
Interleukin 6	+	—	—
Interleukin 1 receptor antagonist	+	+	—
Hyaluronic acid	+	—	—
S100A12 protein	+	ND	+
Matrix metalloproteinase-3	+	ND	ND
Erythrocyte sedimentation rate	+	?	+
C-reactive protein	+	?	+

sion molecule expression, effector enzymes, and signaling pathways. The results are summarized in Table 2^{5,6,11,16-22}.

Damage. Damage may occur in the cartilage or in the bone compartment, and may include change in bone mineral density (BMD), bone destruction, or new bone formation such as syndesmophyte formation or ankylosis. Studies of serum biomarkers in bone have shown no correlation between TNF-related apoptosis-inducing ligand (TRAIL) or osteoprotegerin (OPG) and low BMD in PsA. Increased levels of crosslinked telopeptide of collagen-I, urinary deoxypyridinoline (CTX-I), and OPG may reflect increased bone resorption but was countered by an increase in alkaline phosphatase, resulting in bone formation²³. No longitudinal data are available.

Soluble IL-2 receptor correlates with the development of erosive disease in PsA⁸. Circulating osteoclasts are increased, may be a biomarker for erosive disease, and are sensitive to change following TNF- α blockade²⁴. Polymorphisms in TNF- α and TNF- β are significantly associated with joint erosions in PsA and progression of joint erosions in early PsA. TNF - α gene polymorphisms may be useful prognostic markers for damage²⁵. Clinical improvement also correlates with reduction in serum cartilage oligomeric matrix protein levels, indicating reduction in cartilage loss²⁶.

Biomarkers in skin. Studies of the pathogenesis and treatment of psoriasis have greatly benefited from the fact that both psoriatic plaques and uninvolved skin are accessible to repeated

biopsy. Several studies demonstrated important pathogenic roles of Th17 and Th1 T cells, plasmacytoid and myeloid dendritic cells, activated endothelial cells, and keratinocytes bearing the regenerative maturation phenotype²⁷⁻³⁸. Immunocytochemistry, flow cytometry, RT-PCR, and DNA array analyses have generated large lists of biomarkers, some of which have been validated in clinical trials with cyclosporin, phototherapy, calcipotriol, calcitriol, corticosteroids, retinoids, 6 thioguanine, alefacept, efalizumab, etanercept, and infliximab (Table 3)^{30,31,33,39-52}. Biomarkers in skin have been instrumental for understanding the pathogenesis of psoriasis and mechanism of action of psoriasis therapies. Biomarkers have been used as surrogate treatment endpoints in early, short-term, proof of concept studies^{38,45,53}.

Immunocytochemical biomarkers include those identifying members of the inflammatory infiltrate (e.g., T cells, dendritic cells, neutrophils, macrophages), transcription factors [e.g., activated nuclear factor- κ B (NF- κ B)], and markers of keratinocyte activation or regenerative maturation (keratin K-16, Ki-67, filaggrin, involucrin, epidermal thickness, intercellular adhesion molecule-1, and HLA-DR expression). RT-PCR has demonstrated increased mRNA expression of multiple chemokines [e.g., IL-8, MIG (monokine inducible by interferon gamma), IP-10 (inducible protein-10), MIP3 α (macrophage inflammatory protein3 α)], cytokines (e.g., IL-12, IL-23, interferon- γ , IL-6, IL-1 β , IL-8, IL-22, IL-20),

Table 2. Changes in selected biomarkers in the synovial tissue of patients with psoriatic arthritis (PsA) treated with methotrexate or tumor necrosis factor- α blockade.

	Domain	Treatment	Controls	PsA
Kruithof 2005 ⁵	Diagnosis	—	RA	↑ Vascularity ↑ Neutrophils
Van Kuijk 2006 ⁶	Diagnosis	—	RA	↓ CD3 T cells
Kane 2004 ¹⁶	Active disease	MTX	Post R/	↓ T cells ↓ Macrophages ↓ Adhesion molecules ↓ IL8 gene expression ↓ T cells
Goedkoop 2004 ²²	Active disease	IFX/placebo 48 h	Post R/	↓ Macrophages in sublining ↓ Cell infiltrate ↓ Blood vessels ↓ AlphaVbeta3 expression ↓ Adhesion molecules VEGF unchanged
Goedkoop 2004 ²¹	Active disease	IFX 4 wks	Post R/	↓ Cell infiltrate (T cells and macrophages, not B cells) ↓↓ Macrophage subsets (CD68, CD163, MRP8, and MRP14) ↓ MMP3 and 9
Kruithof 2005 ¹⁸	Active disease SpA	ETC	Post R/	↓ Lymphoid aggregates ↓ Composite histology score ↓ pERK ↓ pJUN ↓ pp38
Canete 2007 ¹⁹	Active disease	MTX	Post R/	
Lories 2008 ²⁰	Active disease	ETC	Post R/	

MTX: methotrexate; IFX: infliximab; ETC: etanercept; Post R: at the end of the treatment period; MRP8: migration inhibitory factor-related protein 8; VEGF: subcutaneous vascular endothelial growth factor.

Table 3. Change in expression of selected biomarkers in clinical trials of biologics in psoriasis vulgaris.

Biomarker	Etanercept ^{27,55-57}	Infliximab ^{51,58}	Alefacept ³⁰	Efalizumab ³¹
CD3	↓	↓	↓	↓
CD4	↓	↓	↓	↓
CD8	↓	↓	↓	↓
CD11c (myeloid dendritic cells)	↓	↓	↓	↓
CD83	↓	ND	↓	↓
Elastase (neutrophils)	↓	ND	ND	ND
Inducible nitric oxide synthase	↓	ND	↓	↓
Interleukin 12/23 p40	↓	ND	↓	ND
Interleukin 23 p19	↓	ND	↓	ND
Interleukin 22	↓	ND	ND	ND
Interleukin 17	↓	ND	ND	ND
Interferon- γ	↓	ND	↓	ND
Signal transducer and activator of transcription-1	↓	ND	↓	ND
Inducible protein 10	↓	ND	ND	ND
Monokine inducible by IFN- γ	↓	ND	↓	ND
Granzyme B	↓	ND	ND	ND
Keratinocyte (intercellular adhesion molecule-1 and/or HLA-DR)*	↓	↓	↓	↓
Interleukin 6	↓	ND	ND	ND
Interleukin 1 β	↓	ND	ND	ND
Interleukin 8	↓	ND	↓	ND
Macrophage inhibitory protein-3 α	↓	ND	ND	ND
Activated nuclear factor- κ B	↓	ND	ND	ND
Interleukin 20	↓	ND	ND	ND
Matrix metalloproteinase-12	↓	ND	ND	ND
Keratin K-16*	↓	↓	↓	↓
Epidermal thickness	↓	↓	↓	↓
Cleaved caspase-3	↑	↑	↑	ND

ND: not done; * \downarrow = \downarrow or absent.

nuclear transcription factors (NF- κ B, STAT-1), MMP-12, antimicrobial peptides, and keratin K-16. DNA array analysis identified over 1300 genes differentially expressed in psoriatic plaques versus nonlesional skin⁵⁴.

In conclusion, only limited data about biological biomarkers in psoriasis and psoriatic arthritis are available. There is an urgent need for a research agenda for development and validation of biomarkers in psoriatic disease.

REFERENCES

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther* 2001;69:89-95.
2. Mildvan D, Landay A, De Gruttola V, Machado SG, Kagan J. An approach to the validation of markers for use in AIDS clinical trials. *Clin Infect Dis* 1997;24:764-74.
3. Maksymowych WP, Landewe R, Boers M, et al. Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. *J Rheumatol* 2007;34:634-40.
4. Batliwalla FM, Li W, Ritchlin CT, et al. Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. *Mol Med* 2005;11:21-9.
5. Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. *Arthritis Res Ther* 2005;7:R569-80.
6. van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. *Ann Rheum Dis* 2006;65:1551-7.
7. Elkayam O, Yaron I, Shirazi I, Yaron M, Caspi D. Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. *Rheumatol Int* 2000;19:101-5.
8. Macchioni P, Boiardi L, Cremonesi T, et al. The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A. *Rheumatol Int* 1998;18:27-33.
9. Elkayam O, Yaron I, Shirazi I, Yaron M, Caspi D. Serum levels of hyaluronic acid in patients with psoriatic arthritis. *Clin Rheumatol* 2000;19:455-7.
10. Foell D, Kane D, Bresnihan B, et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. *Rheumatology Oxford* 2003;42:1383-9.
11. Gratacos J, Casado E, Real J, Torre-Alonso JC. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. *Ann Rheum Dis* 2007;66:493-7.

12. Mastroianni A, Minutilli E, Mussi A, et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. *Br J Dermatol* 2005;153:531-6.
13. Ribbens C, Martin y Porras M, Franchimont N, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. *Ann Rheum Dis* 2002;61:161-6.
14. Cordiali-Fei P, Trento E, D'Agosto G, et al. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. *Ann NY Acad Sci* 2007;1110:578-89.
15. Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. *Arthritis Rheum* 2002;46:2776-84.
16. Kane D, Gogarty M, O'Leary J, et al. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. *Arthritis Rheum* 2004;50:3286-95.
17. Kane D, Roth J, Frosch M, Vogl T, Bresnihan B, FitzGerald O. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. *Arthritis Rheum* 2003;48:1676-85.
18. Kruihof E, De Rycke L, Roth J, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. *Arthritis Rheum* 2005;52:3898-909.
19. Canete JD, Santiago B, Cantaert T, et al. Ectopic lymphoid neogenesis in psoriatic arthritis. *Ann Rheum Dis* 2007;66:720-6.
20. Lories R, Derese I, Luyten FP, de Vlam K. Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. *Clin Exp Rheumatol* 2008;26:96-102.
21. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. *Arthritis Res Ther* 2004;6:R326-34.
22. Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. *Ann Rheum Dis* 2004;63:769-73.
23. Grisar J, Bernecker PM, Aringer M, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. *J Rheumatol* 2002;29:1430-6.
24. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. *J Clin Invest* 2003;111:821-31.
25. Balding J, Kane D, Livingstone W, et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. *Arthritis Rheum* 2003;48:1408-13.
26. Cauza E, Hanusch-Enserer U, Frischmuth K, Fabian B, Dunky A, Kostner K. Short-term infliximab therapy improves symptoms of psoriatic arthritis and decreases concentrations of cartilage oligomeric matrix protein. *J Clin Pharm Ther* 2006;31:149-52.
27. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. *J Immunol* 2005;175:2721-9.
28. Gottlieb AB. Psoriasis: emerging therapeutic strategies. *Nat Rev Drug Discov* 2005;4:19-34.
29. Gottlieb AB. Clinical research helps elucidate the role of tumor necrosis factor-alpha in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. *Lupus* 2003;12:190-4.
30. Chamian F, Lowes MA, Lin SL, et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. *Proc Natl Acad Sci USA* 2005;102:2075-80.
31. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). *Proc Natl Acad Sci USA* 2005;102:19057-62.
32. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. *Nature* 2007;445:866-73.
33. Gottlieb AB, Grossman RM, Khandke L, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. *J Invest Dermatol* 1992;98:302-9.
34. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. *J Exp Med* 2005;202:135-43.
35. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. *J Clin Invest* 2004;113:1664-75.
36. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. *J Exp Med* 2004;199:731-6.
37. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. *J Exp Med* 2004;199:125-30.
38. Gottlieb AB, Cooper KD, McCormick TS, et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. *Curr Med Res Opin* 2007;23:1081-92.
39. Gottlieb S, Hayes E, Gilleaudeau P, Cardinale I, Gottlieb AB, Krueger JG. Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes. *J Cutan Pathol* 1996;23:404-18.
40. Berth-Jones J, Fletcher A, Hutchinson PE. Epidermal cytokeratin and immunocyte responses during treatment of psoriasis with calcipotriol and betamethasone valerate. *Br J Dermatol* 1992;126:356-61.
41. Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. *J Exp Med* 2000;192:681-94.
42. Chamian F, Lin SL, Novitskaya L, et al. Presence of "inflammatory" dendritic cells in psoriasis vulgaris lesions and modulation by efalizumab (anti-CD11a). *J Invest Dermatol* 2004;122:A41-245.
43. Murphy FP, Coven TR, Burack LH, et al. Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: evidence for selective effects on activated T lymphocytes. *Arch Dermatol* 1999;135:1495-502.
44. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. *Nat Med* 1995;1:442-7.
45. Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. *J Am Acad Dermatol* 2000;42:428-35.
46. Gottlieb AB, Lebwohl M, Shirin S, et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. *J Am Acad Dermatol* 2000;43:595-604.

47. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. *Arch Dermatol* 2002;138:591-600.
48. Zhou X, Krueger JG, Kao MC, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. *Physiol Genomics* 2003;13:69-78.
49. Vallat VP, Gilleaudeau P, Battat L, et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. *J Exp Med* 1994;180:283-96.
50. Krueger JG, Wolfe JT, Nabeya RT, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. *J Exp Med* 1995;182:2057-68.
51. Gottlieb AB, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. *J Am Acad Dermatol* 2003;48:68-75.
52. Lu I, Gilleaudeau P, McLane JA, et al. Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infiltration in psoriatic plaques by topical calcitriol. *J Cutan Pathol* 1996;23:419-30.
53. Gottlieb AB, Gottlieb SB, Stern D, et al. Biological activity of CC-10004 in patients with severe plaque-type psoriasis [abstract]. *J Am Acad Dermatol* 2006;54:AB9.
54. Zhou A, Scoggin S, Gaynor RB, Williams NS. Identification of NF-kappa B-regulated genes induced by TNF-alpha utilizing expression profiling and RNA interference. *Oncogene* 2003;22:2054-64.
55. Malaviya R, Sun Y, Tan JK, et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. *J Am Acad Dermatol* 2006;55:590-7.
56. Tan JK, Aphale A, Malaviya R, Sun Y, Gottlieb AB. Mechanisms of action of etanercept in psoriasis. *J Invest Dermatol Symp Proc* 2007;12:38-45.
57. Lizzul PF, Aphale A, Malaviya R, et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. *J Invest Dermatol* 2005;124:1275-83.
58. Malaviya R, Sun Y, Tan JK, Magliocco M, Gottlieb AB. Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis. *J Drugs Dermatol* 2006;5:890-3.